Accumulating evidence reveals that genetic variants play pivotal roles in familial atrial fibrillation (AF). However, the molecular defects in most patients with AF remain to be identified. Here, we report on three novel KCNA5 mutations that were identified in 4 of 120 unrelated AF families. Among them, T527M was found in two AF families, and A576V and E610K in two other AF families, respectively. The mutations T527M and A576V were also detected in 2 and 1 of 256 patients with idiopathic AF, respectively. The same mutations were not observed in 200 secondary AF patients and 500 controls. Functional analyses revealed consistent loss-of-function effects of mutant KCNA5 proteins on the ultrarapidly activating delayed rectifier potassium currents. These findings expand the spectrum of mutations in KCNA5 linked to AF and provide new insight into the molecular mechanism involved in AF.
INTRODUCTION
Atrial fibrillation (AF) is the most common cardiac rhythm disorder in clinical practice. 1 During the lifetime of men and women aged X40 years, there is about 25% risk for the development of AF. 2 This arrhythmia may result in irregular ventricular response, tachycardiamediated cardiomyopathy, heart failure and thromboembolism. 3 AF accounts for nearly one-third of strokes in individuals above 65 years of age, and is also an independent predictor of mortality. 4 AF is often associated with structural heart diseases or systemic disorders, such as hypertension, coronary artery disease, heart failure, rheumatic heart disease, hyperthyroidism and cardiomyopathies. 5 However, in nearly 10-20% of cases, the underlying etiology for AF cannot be identified by routine examination, and such AF is termed 'idiopathic' . 6 Emerging evidence has strongly suggested hereditary determinants for AF. 7, 8 Genome-wide scan revealed loci on human chromosomes 10q22, 9 6q14-16 10 and 5p15 11 that are linked to familial AF. Specific variations in several genes associated with AF were identified and characterized. These AF-related genes are mainly as follows: KCNQ1, which encodes the a-subunit of slowly activating delayed rectifier potassium channel (IKs); 12 HERG, which encodes the a-subunit of the rapidly activating delayed rectifier potassium channel (IKr); 13 SCN5A, which encodes the a-subunit of the sodium channel; 14, 15 Ankyrin-B, which encodes a member of a family of versatile membrane adapters, which is required for coordinated assembly of the Na/Ca exchanger, Na/K ATPase and inositol trisphosphate receptor at transverse tubule/sarcoplasmic reticulum sites in cardiomyocytes; 16 KCNJ2, which encodes the a-subunit of inward rectifier potassium channel (IK1); 17 KCNA5, which encodes the a-subunit of the ultrarapidly activating delayed rectifier potassium channel (Kv1.5); 18 Connexin 40, which is expressed selectively in atrial myocytes and mediates the coordinated electrical activation of the atria; 19 KCNE1, which encodes the b-subunit of IKs; 20 KCNE2 encoding b-subunit of IKr; 21 and KCNE3, 22 KCNE4 23 and KCNE5, 24 which encode the b-subunits of potassium channels interacting with KCNQ1, HERG and others. In addition, inheritable defects also confer substantial disease susceptibility on patients with secondary AF. 25 Nevertheless, AF is a genetically heterogeneous disorder, and genetic defects in a significant proportion of AF patients remain to be identified. 26 In this study, we describe the identification and characterization of novel KCNA5 mutations as genetic determinants for AF.
MATERIALS AND METHODS

Study subjects
A total of 120 unrelated kindreds with familial AF were identified among the Chinese population. Peripheral venous blood specimens were prepared and clinical data, including medical records, electrocardiogram (ECG) and echocardiography reports, were collected. In addition, 256 unrelated sporadic patients with idiopathic AF were also collected. The controls were 200 unrelated patients with secondary AF and 500 ethnically matched healthy subjects. All study subjects were of Chinese Han descent. The study subjects were clinically classified using a consistently applied set of definitions. 11, 26 Briefly, 'lone AF' was defined as AF in individuals o60 years of age without hypertension or overt structural heart disease by clinical examination, ECG and echocardiography. 'Familial AF' was the lone AF in family members with X2 first-degree relatives with documented lone AF. Relatives with AF occurring at any age in the setting of structural heart disease (hypertensive, ischemic, myocardial or valvular) were classified as 'undetermined' for having an inherited form of AF. The 'undetermined' classification was also used if documentation of AF on an ECG tracing was lacking in relatives with symptoms consistent with AF (palpitations, dyspnea and light-headedness), or if a screening ECG and echocardiogram were not carried out, regardless of the symptoms. Relatives were classified as 'unaffected' if they were X18 years of age, asymptomatic and had a normal ECG. We have described 'secondary AF' as AF secondary to structural heart diseases or systemic disorders, such as heart failure and hyperthyroidism. Genomic DNA from all participants was extracted from blood lymphocytes with the Wizard Genomic DNA Purification Kit (Promega, Madison, WI, USA). The study was carried out according to the terms required by the Research Ethics Committee of Tongji University School of Medicine. Written informed consent was obtained from all participants.
Genetic investigations
We initially screened 12 established AF susceptibility genes (KCNQ1, HERG, SCN5A, Ankyrin-B, KCNJ2, KCNE1, KCNE2, KCNE3, KCNE4, KCNE5, KCNA5 and Connexin 40) in 120 probands and identified only three mutations in the KCNA5 gene in 4 of 120 probands. Subsequently, we targeted the KCNA5 gene in the members of the four families carrying identified KCNA5 mutations-256 patients with idiopathic AF, 200 patients with secondary AF and 500 controls. The primers used to amplify the complete coding regions and exon/intron boundaries of these candidate genes were designed with the online Primer 3 software. PCR was carried out using Hot-Star Taq DNA Polymerase (Qiagen, Hilden, Germany). Amplified products were purified with the QIAquick gel extraction kit (Qiagen). Both strands of each PCR product were sequenced with a DYEnamic ET dye terminator kit (Amersham Biosciences, Little Chalfont, Buckinghamshire, UK) using MegaBACE 500 DNA Sequencing system (Amersham Biosciences, Piscataway, NJ, USA).
Sequence comparison
The multiple Kv1.5 protein sequences from various species were aligned using the software ClustalW.
Site-directed mutagenesis
The full-length wild-type cDNA of human KCNA5 was obtained by PCR and inserted into plasmid pGEM-4Z (Promega). Every mutation was introduced into a wild-type KCNA5 clone with a QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene, San Diego, CA, USA). Clones were sequenced to confirm the desired mutation and exclude any other sequence variants. The appropriate wild-type and mutant KCNA5 cDNAs were transferred into vector pXOOM with enhanced green fluorescent protein (pXOOM-EGFP, a kind gift from Thomas Jespersen, Department of Medical Physiology, The Panum Institute, University of Copenhagen, Denmark). The resulting KCNA5-pXOOM constructs were corroborated by sequencing before subsequent experiments.
Cell transfection and electrophysiology
COS-7 cells were transiently transfected with 2 mg of wild-type, or 2 mg of mutant, or both 1 mg of wild-type and 1mg of mutant KCNA5-pXOOM DNAs using Lipofectamine (Invitrogen, Carlsbad, CA, USA). Using the whole-cell patchclamp technique in the voltage-clamp mode, expressed Kv1.5 channels in transfected COS-7 cells were explored after transfection for 48 h. Voltage-step protocols are detailed in figure legends. Patch electrodes, with 5-7 MO resistance, were filled with the solution (in mM) of 120 KCl, 1 MgCl 2 , 5 EGTA and 10 HEPES supplemented with 5 mM of ATP, pH 7.3. Cells were superfused with the solution (in mM) of 136.5 NaCl, 5.4 KCl, 1 MgCl 2 , 1.8 CaCl 2 , 5.5 HEPES and 10 glucose, pH 7.3. Current density was obtained by normalizing whole-cell currents on the basis of individual cell capacitance. Experiments were carried out at room temperature (22 1C).
Statistics
Data are given as mean±s.e.m. Differences between the two groups were compared using w 2 -or Student's t-test for continuous variables. All tests were twotailed, with a P-value o0.05 defined as being statistically significant. 
RESULTS
KCNA5 mutations in AF kindreds and patients with idiopathic AF
We identified three novel heterozygous missense mutations in KCNA5 from 4 of the 120 unrelated kindreds with AF. The pedigree structures of the four kindreds are illustrated in Figure 1 . The total population prevalence of KCNA5 mutations based on probands was approximately 3.3%. A 1580 C-T mutation, predicting the substitution of methionine (Met, M) for threonine (Thr, T) at codon 527 (Thr527-Met) was identified in 2 ( Figures 1a and b) of 120 families. A 1727 C-T mutation, corresponding to the conversion of alanine (Ala, A) into valine (Val, V) at amino-acid residue 576 (Ala576-Val), was found in a third family (Figure 1c) . A 1828 G-A mutation, resulting in the transition of glutamic acid (Glu, E) into lysine (Lys, K) at 610 (Glu610-Lys), was observed in a fourth family (Figure 1d ). The detected substitutions in KCNA5 are shown in Figure 2 . These mutations cosegregated with AF in these families, with the exception of III-2 in family A, IV-1 and IV-7 in family C, and III-1 in family D, pointing to the fact that the long-term follow-up of asymptomatic subjects carrying the allele encoding Met527, Val576 or Lys610 will be needed to confirm its clinical significance. In addition, the heterozygous variants Met527 and Val576 were also identified in 2 and 1 of 256 unrelated sporadic patients with idiopathic AF, respectively. The phenotypic characteristics and results of genetic screening of the pedigree members and sporadic patients with idiopathic AF are listed in Table 1 . However, the same mutations were not detected in 200 patients with secondary AF and 500 ethnically matched controls. In the other 11 investigated genes, no more mutations were identified in the 120 probands, except those that were reported earlier. 12, 17, 21 Multiple alignment of the Kv1.5 protein sequences across species A cross-species alignment of Kv1.5 protein sequences showed that the altered amino acids, except for Ala576, are completely conserved evolutionarily (Figure 3 ). in the net outward current compared with that generated by the expression of wild-type KCNA5 alone (Figure 4 ). These data indicate that the mutant proteins coassemble into functional channels with wild-type subunits, exerting consistent loss-of-function effects on I Kur in the heterozygous state.
DISCUSSION
The cardiac repolarization process is regulated by several outward currents, of which the ultrarapid delayed rectifier potassium current (I Kur ) is thought to play a major role in the repolarization of human atrial myocytes. 27 I Kur is carried by functional channel Kv1.5 assembled Representative current traces were recorded from COS-7 cells transfected with wild-type and mutant KCNA5, respectively, and from COS-7 cells cotransfected with wild-type and a different mutant, KCNA5. Current density is plotted versus voltage for the indicated transfections. Cells were held at À40 mV before depolarization to various potentials ranging from À40 to +40 mV in 10-mV increments for 200 ms, and thereafter held at À30 mV for 60 ms. Typical current traces were acquired from COS-7 cells with similar capacitance on rows.
KCNA5 mutations and atrial fibrillation Y Yang et al Figure 3 Multiple alignment of the Kv1.5 protein sequences across species. The amino acids of Thr527 and Glu610 are highly conservative evolutionarily across species.
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by KCNA5-encoded pore-forming a-subunits. The Kv1.5 channel activates and deactivates rapidly, whereas it inactivates only slowly and incompletely. In this study, we report three earlier unrecognized missense mutations, that is, T527M, A576V and E610K, in KCNA5 from 4 of 120 unrelated AF kindreds with a prevalence of approximately 3.3%. Electrophysiological research into the expressed mutant proteins shows consistent loss-of-function effects on I Kur . The loss-of-function effects of the KCNA5 mutations identified in patients with AF suggest an alternative AF mechanism, which is likely to be due to the prolonged effective refractory period and enhanced propensity for early afterdepolarization, which is exacerbated with sympathetic stimulation. Given the presence of a mutant protein, increased nerve tone as a common precipitant renders affected patients susceptible to AF, presumably by amplifying the already abnormal myocardial electrophysiology.
Association of defective Kv1.5 with susceptibility to AF was highlighted both in vitro and in vivo. 18 In human atrial myocytes, Kv1.5 loss-of-function mimicked by Kv1.5 blockade with 4-aminopyridine was accompanied by significant prolongation of action potential duration and associated with a predisposition to early afterdepolarization and paroxysmal oscillations in membrane potential that interrupted normal repolarization. Under the condition of adrenergic agonist administration, human atrial myocytes with Kv1.5 channel blocked were concomitant with remarkably increased triggered activity. Besides, the vulnerability to adrenergic stress was also observed in the KCNA5 Glu375X mutation-carrying patient, in whom isoproterenol infusion elicited irregular atrial discharges evolving into overt AF. These findings attest the pathogenic link between compromised Kv1.5 function and susceptibility to AF.
Functionally deficient KCNA5 as a genetic determinant for AF is exciting, especially in optimizing AF therapy. It is well known that existing medication with class I or III antiarrhythmic agents, such as dofetilide and sotalol, 28, 29 could bring about negative feedback impact on the ventricular repolarization, which is generally considered as a critical risk factor for fatal arrhythmias. These life-threatening adverse effects, attributable to the unselective blockade of the potassium currents in both atrial and ventricular cardiomyocytes, 30 hindered the appropriate application of these antiarrhythmic drugs to patients in clinical practice. Given these limitations, new agents targeting the atrium-selective current may well be an appealing alternative for AF therapy. 31 Specifically functioning in the atria, I kur, is a crucial determinant for phase I repolarization during action potentials. 32, 33 The strong evidence that KCNA5 expresses much more extensively in human atria than in ventricles, and that I Kur has not been recorded in the human ventricle, 32, 34 implicates Kv1.5 as a potential selective target for the medical management of AF. 35 Importantly, it should be noted that traditional therapeutics for AF are based on inhibition of I Kur , 31 and would not be applicable in patients with loss of function of Kv1.5. Therefore, it is required to genotype KCNA5 in patients before treatment with Kv1.5-targeted agents for AF.
In conclusion, we identified novel KCNA5 mutations as genetic determinants for AF. Playing a role in AF pathogenesis, but not in ventricular function, KCNA5 genetic defects signify important implications for genetic diagnosis, genetic counseling and atrium-selective strategy for AF therapy.
